Homepage Top Section1

VIR-2703 is a result of the recently announced expansion of the firms’ multi-target existing collaboration for the development and commercialisation of RNAi therapeutics for infectious diseases. The partnership

The open-label and phase 3 SIMPLE trial has assessed five-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalised patients with severe manifestations of COVID-19 disease.

Follicular lymphoma, which is said to be the second most common form of non-Hodgkins lymphoma (NHL), is an indolent lymphoma and represents around 22% of NHL cases. Claimed

In this regard, Gilead Sciences and Kite have signed a three-year research collaboration agreement with oNKo-innate on cancer immunotherapies with an objective to support the discovery and development

The deal is said to leverage TScan’s advanced platform to discover novel cancer antigens, which are expected to be targeted by TCR-based therapies. TScan chief scientific officer Gavin

Braftovi, an oral small molecule kinase inhibitor, has been developed to target BRAF V600E. The approval was based on data from the BEACON CRC trial, which is claimed

In this connection, the RNAi therapeutics company completed the rolling submission of a new drug application (NDA) for lumasiran with the regulator. Considered to be an ultra-rare, life-threatening

IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The FDA fast track designation will enable the development and accelerate the review of

The company, which is a subsidiary of Roche, will evaluate the safety and efficacy of Actemra given intravenously plus standard of care in hospitalised adults with severe COVID-19